Metastatic bone disease accompanies malignant tumors in urology with a high prevalence. Bisphosphonates are the choice of the treatment in the frame of complex oncology approaches. We present our experiencies with fifteen years application of clodronate to patients with urologic malignancies.
Bone metastasis are very frequent in solid tumours, urological malignancies not excluded. Metastatic bone involvement and related SRE (skeletal related events) shortens survival and significantly influences patient´s quality of life. Bisphosphonates therapy is a part of comprehensive approach in metastatic cancer patients. Modern trends using cytotoxic effect of bisphosphonates represent consecutive shift from palliative to curative adjuvant therapy.
As for the frequency, urinary tract infections occupy the second position in our social and economical environment. GPs and other specialists participate on therapy of UTI. Tissue infections belong to urologists. Emergence and progress of the disease into chronic stadium have been caused by incorrect or insufficient therapeutic modality. In case of late diagnosis and therefore delayed proper therapy such care costs much more. Moreover quality of life of these patients and their relatives become worse. Optimal diagnostic and therapeutic steps in UTI are described.
- MeSH
- androgeny agonisté MeSH
- hormonální substituční terapie MeSH
- karcinom radioterapie MeSH
- nádory prostaty radioterapie MeSH
- Publikační typ
- kongresy MeSH
- MeSH
- bisfosfonáty farmakologie terapeutické užití MeSH
- urologické nádory diagnóza sekundární terapie MeSH
- Publikační typ
- kongresy MeSH
